Oncology & Cancer

Researchers harness immune system to fight pancreatic cancer

(Medical Xpress)—Pancreatic cancer ranks as the fourth-leading cause of cancer death in the United States, and is one of the most deadly forms of cancer, due to its resistance to standard treatments with chemotherapy and ...

Oncology & Cancer

Targeting pancreatic cancer drug resistance

Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%. Novel therapies are urgently needed, as conventional and targeted approaches have not been successful and ...

Oncology & Cancer

ASCO updates recs on potentially curable pancreatic cancer

(HealthDay)—Guidelines relating to the appropriate adjuvant regimen for patients with pancreatic cancer have been updated in light of new evidence, according to a special article published online April 11 in the Journal ...

Oncology & Cancer

New study finds two-drug combo slows advanced pancreatic cancer

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was ...

page 2 from 5